Sun Pharma opens first production unit in Egypt
Sun Pharma's first production unit in Egypt involving a total investment of USD 12.5 million has been inaugurated, signalling growing bussines ties between India and the key Middle East...22-02-2017
22-02-2017
Clarifies on News Item
With reference to news appeared in CNBC TV 18 dated February 16, 2017 "UK Regulator approves Sun Pharma Generic drug of Tobramycin.", Sun Pharmaceutical Industries Ltd has submitted to BSE a copy of Clarification is enclosed.16-02-2017
Clarification sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on February 16, 2017, with reference to news appeared in CNBC TV 18 dated February 16, 2017 "UK Regulator approves Sun Pharma Generic drug of Tobramycin."The reply is awaited.16-02-2017
Key Sun Pharma drugs to bid Halol goodbye
Halol plant is key for Sun Pharma and contributed in high single digits to its US sales16-02-2017
Sun Pharma Reports Surprise Drop In Profits
The company has spent months trying to resolve the concerns, but the FDA remains dissatisfied and outlined further problems with the plant in an inspection report in December.14-02-2017
Results Press Release for December 31, 2016
Sun Pharmaceutical Industries Ltd has informed BSE about : 1. Result Press Release for the period ended December 31, 201614-02-2017
Outcome of Board Meeting
Sun Pharmaceutical Industries Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2017, inter alia, has approved the following;1. The Board of Directors of the Company appointed Mr. Kalyanasundaram Subramanian as an Additional Director of the Company with immediate effect.2. The Board of Directors of the Company have, subject to the approval of the members of the Company at the ensuing...14-02-2017
Announces Q3 results (Standalone & Consolidated) & Limited Review Report (Standalone & Consolidated) for the Quarter ended December 31, 2016
Sun Pharmaceutical Industries Ltd has announced the following results for the quarter ended December 31, 2016:The Unaudited Standalone results for the Quarter ended December 31, 2016The Company has posted a net loss of Rs. (1626.60) million for the quarter ended December 31, 2016 as compared to net loss of Rs. (1422.70) million for the quarter ended December 31, 2015. Total Income has increased from Rs. 19283.90 million for the quarter...14-02-2017
Outcome of Allotment Committee MeetingThis is to inform you that the Allotment Committee of Directors at its meeting held today i.e. on Tuesday, February 14, 2017, allotted 20,993(Twenty Thousand Nine Hundred and Ninety Three) equity shares of the Company of Re. 1/- (Rupee One Only) each, on exercise of stock options under the Sun Employee Stock Option Scheme - 2015.Accordingly, post the above allotment the paid-up equity share capital of the Company is Rs. 2,39,92,91,18
Sun Pharmaceutical Industries Ltd has informed BSE about Outcome of Allotment Committee Meeting held on February 14, 2017.14-02-2017
Sun Pharmaceuticals Industries Ltd
Taro Pharmaceutical Industries Ltd, the US subsidiary of Sun Pharmaceuticals Industries Ltd, has received tentative approval from the US Food and Drug Administration for diclofenac sodium topical...08-02-2017